Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis
Just a month after the FDA signed off on the first US study for an off-the-shelf CAR-T therapy from Cellectis $CLLS, its partners at Servier …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
